Genprex Collaborators: Positive Preclinical Data on Reqorsa, Gene Therapy for Lung Cancer

 Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer Treatments

REQORSA Has Anti-Tumor Mechanisms and Ability to Trigger Cancer Cell Death

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company's non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which is being held April 5-10, 2024 in San Diego, California.

https://www.biospace.com/article/releases/genprex-collaborators-report-positive-preclinical-data-on-the-use-of-reqorsa-and-on-nprl2-gene-therapy-utilizing-non-viral-oncoprex-delivery-system-for-the-treatment-of-lung-cancers-at-the-2024-aacr-annual-meeting/